Compares IMA203 cell therapy with standard treatments in melanoma

Trial details

Who runs it

Immatics US, Inc.

Trial code

NCT06743126EU 2024-517062-42-00

Record updated

30 October 2026

Original description

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM).Read full original descriptionShow less

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM).

For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

Inclusion: Pathologically confirmed and documented cutaneous melanoma or mucosal melanoma. CM patients (including acral melanoma and melanoma of unknown primary) and mucosal melanoma patients with unresectable or metastatic disease; Positive for HLA-A*02:01 or one of its P-group alleles; Adequate selected organ function per protocol; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor, applied either as monotherapy or in combination with other therapies as treatment for unresectable or metastatic melanoma; Patients with BRAF mutation should have been treated with one prior line of BRAF-directed therapy (with or without a MEK inhibitor) prior to initial eligibility assessment, unless deemed not clinically indicated at Investigator's discretion due to concurrent medical condition, prior toxicity, or if declined by the patient; Life expectancy more than 6 months; Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Female patient of childbearing potential must use adequate contraception from randomization until 12 months after the infusion of IMA203 or in line with the instructions provided for investigator's choice treatment (in the control arm); Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203 or in line with the instructions provided for investigator's choice treatment (in the control arm); The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to randomization and prior to trial treatment start.

Exclusion: Prior allogenic stem cell transplantation or solid organ transplantation; Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study; History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician; History of hypersensitivity to CY, FLU, or IL-2 or presence of any contraindications and other limitations for planned treatment with investigator's choice as laid down in the current versions of the respective PIs / SmPCs; History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the investigator; Patient has received systemic corticosteroids within 2 weeks prior to leukapheresis,; Patient has received surgery or other anti-cancer therapies, any agent that is likely to suppress bone marrow function, or investigational medicinal products within 7 days prior to leukapheresis; Patients who underwent non-myeloablative lymphodepletion prior to cell therapy within the last 6 months; Prior treatment with IMA203; Concurrent treatment in another clinical trial or a device study that could interfere with the IMA203 treatment or planned investigator's choice treatment; Patient has received any investigational therapies, inactivated vaccines, chronic use of systemic corticosteroids or IV antibiotics within 1 week prior to randomization, or live vaccines within 4 weeks prior to randomization; Patient has received any anti-cancer therapy (prior anti-cancer treatment or bridging therapy) or radiotherapy within 1 week prior to start of trial treatment; History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years; Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents; History of cardiac conditions as per protocol; Known hypersensitivity to any of the rescue medications; Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection; Any condition contraindicating leukapheresis; Any other condition that would, in the investigator's or sponsor's judgment, contraindicate the patient's participation in the clinical trial because of safety concerns or compliance with clinical trial procedures (e.g., psychiatric disorders or substance dependence, neurological impairment); Patients with any active infection or ongoing reactivation of infection; Patients with LDH greater than 2.0-fold ULN; Uveal melanoma; Pregnant or breastfeeding; Patients with ascites, pleural or pericardial effusion which requires repeated (2 within 4 weeks) or continuous paracentesis, thoracentesis or pericardiocentesis within last 2 months; Patients with active brain metastases or leptomeningeal metastases; Other protocol defined inclusion/exclusion criteria could apply.

ClinicalTrials.gov NCT06743126 · EU CTIS 2024-517062-42-00